Ocuphire to Participate in the 2021 BIO CEO & Investor Conference and Cantor Fitzgerald’s Panel on Eyeing Key Events in the Ophthalmology Space in 2021

Ocuphire将参加2021年BIO首席执行官和投资者会议以及Cantor Fitzgerald关于2021年眼科领域关键事件的小组讨论

2021-02-12 16:59:24 BioSpace

本文共1249个字,阅读需4分钟

FARMINGTON HILLS, Mich., Feb. 11, 2021 -- Ocuphire Pharma, Inc. , a clinical-stage ophthalmic biopharmaceutical company focused on developing and commercializing therapies for the treatment of several eye disorders, announced today that Mina Sooch, Chief Executive Officer will present a corporate overview at the 2021 BIO CEO & Investor Conference and participate in select one-on-one investor meetings from February 16 to 18, 2021. Ocuphire’s management will also participate in Cantor Fitzgerald’s Eyeing Key Events and Programs in the Ophthalmology Space in 2021 Panel on February 19, 2021 at 10:30am EST. Beginning February 16th, a pre-recorded presentation by company management will be available for on-demand viewing by registered attendees anytime through March 14th by accessing the BIO CEO Conference portal. For more information about the BIO CEO & Investor Conference, please refer to the conference website at https://www.bio.org/events/bio-ceo-investor-digital-conference To register in advance for Cantor Fitzgerald’s Eyeing Key Events and Programs in the Ophthalmology Space in 2021 Panel on February 19, 2021, sign up here. About Ocuphire Pharma Ocuphire is a publicly traded (NASDAQ: OCUP), clinical-stage ophthalmic biopharmaceutical company focused on developing and commercializing therapies for the treatment of several eye disorders. Ocuphire’s pipeline currently includes two small-molecule product candidates targeting front and back of the eye indications. The company’s lead product candidate, Nyxol® Eye Drops, is a once-daily preservative-free eye drop formulation of phentolamine mesylate, a non-selective alpha-1 and alpha-2 adrenergic antagonist designed to reduce pupil size, and is being developed for several indications, including dim light or night vision disturbances (NVD), reversal of pharmacologically-induced mydriasis (RM), and presbyopia, and has been studied in 7 Phase 1 and 2 trials. Ocuphire’s second product candidate, APX3330, is an oral tablet designed to inhibit angiogenesis and inflammation pathways relevant to retinal and choroidal vascular diseases, such as diabetic retinopathy (DR) and diabetic macular edema (DME), and has been studied in 11 Phase 1 and 2 trials. Nyxol is entering Phase 3 clinical development for NVD and RM, and Phase 2 for presbyopia. APX3330 is entering Phase 2 clinical development for DR/DME. As part of its strategy, Ocuphire will continue to explore opportunities to acquire additional ophthalmic assets and to seek strategic partners for late-stage development, regulatory preparation and commercialization of drugs in key global markets. Please visit www.clinicaltrials.gov to learn more about Ocuphire’s completed Phase 2 clinical trials and ongoing Phase 3 registration trials (NCT04620213 and NCT04638660) and soon to recruit Phase 2 trials (NCT04675151 and NCT04692688). For more information, please visit www.ocuphire.com. Ocuphire Contacts Mina Sooch, President & CEO Ocuphire Pharma, Inc. ir@ocuphire.com www.ocuphire.com Corey Davis, Ph.D. LifeSci Advisors cdavis@lifesciadvisors.com
密歇根州法明顿山,2021年2月11日--Ocuphire Pharma,Inc.是一家临床阶段眼科生物制药公司,专注于开发和商业化治疗多种眼病的疗法,今天宣布首席执行官米娜·苏奇将在2021年生物首席执行官和投资者会议上介绍公司概况,并参加2021年2月16日至18日举行的精选的一对一投资者会议。Ocuphire的管理层还将于2021年2月19日美国东部时间上午10:30参加Cantor Fitzgerald在2021年眼科空间面板上的虎视眈眈的关键事件和项目。 从2月16日开始,公司管理层预先录制的演示将可供注册与会者随时通过访问BIO首席执行官会议门户观看,直到3月14日。欲了解BIO首席执行官和投资者大会的更多信息,请访问大会网站https://www.BIO.org/events/bio-ceo-investor-digital-conference 要提前注册在2021年2月19日在2021年眼科空间小组的Cantor Fitzgerald的虎视眈眈的关键事件和项目,请在这里注册。 关于Ocuphire Pharma Ocuphire是一家上市公司(纳斯达克市场代码:OCUP),处于临床阶段的眼科生物制药公司,专注于开发治疗多种眼病的疗法并将其商业化。Ocuphire的管道目前包括两个小分子候选产品,分别针对眼睛前和眼睛后的适应症。该公司的主要候选产品NYXOL®滴眼液是一种每日一次的无防腐剂的甲磺酸酚妥拉明滴眼液配方,它是一种非选择性的alpha-1和alpha-2肾上腺素能拮抗剂,旨在缩小瞳孔大小,目前正在开发用于多种适应症,包括昏光或夜视障碍(NVD)、逆转药物诱导的散瞳(RM)和老花眼,并已在7个1期和2期试验中进行研究。Ocuphire的第二个候选产品APX3330是一种口服片剂,设计用于抑制与视网膜和脉络膜血管疾病相关的血管生成和炎症途径,如糖尿病视网膜病变(DR)和糖尿病黄斑水肿(DME),并在11个1期和2期试验中进行了研究。Nyxol治疗NVD和RM正进入3期临床开发阶段,治疗老花眼正进入2期临床开发阶段。APX3330正进入DR/DME的2期临床开发。作为其战略的一部分,Ocuphire将继续探索获取更多眼科资产的机会,并在关键的全球市场为药物的后期开发、监管制备和商业化寻求战略合作伙伴。请访问www.clinicaltrials.gov了解更多关于Ocuphire已完成的2期临床试验和正在进行的3期注册试验(NCT04620213和NCT04638660)以及即将招募的2期试验(NCT04675151和NCT04692688)。欲了解更多信息,请访问www.ocuphire.com。 Ocuphire联系人 米娜·苏奇,总裁兼首席执行官 奥库费尔制药公司。 @ocuphire.com www.ocuphire.com 科里·戴维斯博士。 LifeSci顾问 cdavis@lifesciadvisors.com

以上中文文本为机器翻译,存在不同程度偏差和错误;偶尔因源网页结构局限,内容无法一次完整呈现。请理解并参考原站原文阅读。

阅读原文